Atricure SEC Filings

AtriCure, Inc. (ATRC) director reports option exercises and share sales. On 11/24/2025, the reporting person exercised 5,033 non-qualified stock options at $19.95 per share and sold 5,033 shares of common stock at a weighted average price of $37.32 per share. On 11/25/2025, they exercised an additional 4,967 options at $19.95 and sold 4,967 shares at $38.00 per share.

After these transactions, the director beneficially owned 34,374 shares of AtriCure common stock directly and held 25,000 non-qualified stock options. The options exercised on these dates were originally granted on November 11, 2016 and vest over four years, with 25% after one year and the remainder in monthly installments over the next three years.

AtriCure, Inc. (ATRC) reported an insider stock transaction by its Chief Marketing & Strategy Officer. On 11/26/2025, the officer sold 5,166 shares of AtriCure common stock in an open market transaction coded "S" for sale.

The reported sale price is a weighted average of $37.29 per share, with individual trades executed at prices ranging from $36.51 to $38.44 per share. After this transaction, the officer beneficially owns 78,798 shares of AtriCure common stock, held directly.

AtriCure, Inc. (ATRC) reported an insider share sale by a director. On 11/21/2025, the reporting person sold 3,000 shares of AtriCure common stock in an open-market transaction coded as a sale. The weighted average sale price was $35.72 per share, with individual trade prices ranging from $35.71 to $35.76.

Following this transaction, the director beneficially owns 11,371 AtriCure shares, held directly. The filing notes that detailed trade data for the individual prices and share amounts within the reported range will be provided upon request to the SEC staff, the issuer, or any security holder.

AtriCure, Inc. CEO and President Michael H. Carrel, who also serves as a director, reported a charitable gift of 6,000 shares of AtriCure common stock on 11/13/2025, according to a Form 4 filing. The transaction used code “G,” indicating a gift, and was reported at a price of $0, with the filing noting that no consideration was received for this transfer.

After the reported transaction, Carrel beneficially owns 691,377 shares of AtriCure common stock directly. The filing also lists 9,310 shares held indirectly through his children and 2,250 shares held indirectly through his parents, with a statement that he disclaims beneficial ownership of these indirect holdings except to the extent of his pecuniary interest.

AtriCure (ATRC) reported solid third‑quarter growth and near break‑even results. Revenue rose to $134,269, up 15.8% year over year, with gross margin at 75.5% versus 74.9% a year ago. Operating income was $208, and net loss narrowed to $267, or $0.01 per share. For the first nine months, revenue reached $394,028, up 15.5%.

Growth was led by appendage management and pain management in the United States, while minimally invasive ablation declined as physicians shifted procedures. Cash and cash equivalents were $147,865 with long‑term debt of $61,865 and unused ABL borrowing availability of $61,885 as of September 30, 2025. The company completed enrollment of 6,500 patients in the LeAAPS trial and launched the cryoICE cryoXT probe for amputation pain therapy in the U.S. A sale‑and‑leaseback of a building resulted in a $6,250 financing obligation. Shares outstanding were 49,716,988 as of October 27, 2025.

AtriCure, Inc. (ATRC) filed an Amendment No. 1 to its Form 8-K to add the required signature of a duly authorized representative. The amendment makes no other changes to the original report filed on October 29, 2025.

The company also noted it issued a press release regarding financial results for the third quarter ended September 30, 2025, and scheduled a conference call on October 29, 2025 at 4:30 p.m. Eastern Time. The press release is furnished as Exhibit 99.1.

AtriCure (ATRC) furnished an 8-K announcing third-quarter results communications. The company issued a press release covering financial results for the quarter ended September 30, 2025 and scheduled a conference call on October 29, 2025 at 4:30 p.m. Eastern Time to discuss the results. The press release is provided as Exhibit 99.1 and is incorporated by reference as furnished information.

Insider sale by AtriCure officer: Justin J. Noznesky, Chief Marketing & Strategy Officer and director, sold 3,000 shares of AtriCure, Inc. (ATRC) common stock on 09/12/2025 at a weighted average price of $36.30 per share. After the transaction he beneficially owned 83,964 shares. The Form 4 discloses the sale price range ($36.28–$36.36) and states the reported price is a weighted average; the filer offers to provide detailed trade-by-trade information on request. The form is signed and dated 09/16/2025.

Sven Wehrwein, a director of AtriCure, Inc. (ATRC), executed matched transactions on 08/22/2025. He exercised 5,000 non-qualified stock options with an exercise price of $19.95, acquiring 5,000 shares. He simultaneously sold 5,000 common shares at $37.00. After these transactions he beneficially owned 34,374 shares and held options covering 35,000 shares exercisable through 11/11/2026. The options were originally granted on November 11, 2016, and vest per the schedule disclosed in the filing.